Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
about
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisMoving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.Levodopa/carbidopa/entacapone in Parkinson's disease.Entacapone and prostate cancer risk in patients with Parkinson's disease.Treatment of advanced Parkinson's disease.Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's diseaseLate (Complicated) Parkinson's Disease
P2860
Q26779605-F8AF4A11-F7F9-488F-A4C3-365CA7DBC0A4Q37973462-D3E2F79F-2DCC-4C8A-B9EB-55C2626CFDC6Q37979869-1A6C7683-5A01-4A6B-85D8-0F4B884329CAQ38070888-47221AA4-8B48-436C-A267-2898926BA830Q42626399-A557CC6B-611D-4F06-A677-EB60F1570289Q45934197-E5D10996-BEFE-4CB1-9163-D6EB729C48BDQ53623137-D17DAA53-9452-4B88-A6FC-D6209B84530DQ55645561-4F4C763B-4B8A-4575-9E2F-95A20D4BAFC2Q57192035-6A65FB26-0E49-47C6-81E0-C664BE132468Q58870320-ECEF4156-FFF1-4B25-8DCE-DB5C19A64795
P2860
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Five-year efficacy and safety ...... ents with Parkinson's disease.
@en
Five-year efficacy and safety ...... ents with Parkinson's disease.
@nl
type
label
Five-year efficacy and safety ...... ents with Parkinson's disease.
@en
Five-year efficacy and safety ...... ents with Parkinson's disease.
@nl
prefLabel
Five-year efficacy and safety ...... ents with Parkinson's disease.
@en
Five-year efficacy and safety ...... ents with Parkinson's disease.
@nl
P2093
P2860
P1476
Five-year efficacy and safety ...... ents with Parkinson's disease.
@en
P2093
Helena Nissinen
Mika Leinonen
Mikko Kuoppamäki
P2860
P2888
P304
P356
10.1007/S00702-008-0025-8
P577
2008-02-08T00:00:00Z